Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis
13. November 2019 08:30 ET
|
Innovation Pharmaceuticals, Inc.
Oral cancer incidence increasing worldwide due to spread of human papillomavirus (HPV), Oral SexMillions of patients worldwide suffer from treatment-induced Oral Mucositis (OM)Existing OM therapies...
Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia
28. Oktober 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to highlight preclinical data by...
Innovation Pharmaceuticals Partnering Provides Momentum For Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need
14. Oktober 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
Convened first Joint Development Committee (JDC) meetingData generated to inform internal Brilacidin development efforts in Ulcerative ColitisGoal to develop oral Brilacidin to treat a wide continuum...
Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases
08. Oktober 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of published...
Innovation Pharmaceuticals Clinical Trial of Oral Brilacidin in Ulcerative Colitis Program Expected to Commence in December; Top-Line Data in Q1 2020
03. Oktober 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...
Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm
30. September 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
Objective to further unlock market potential of pipeline and determine the appropriate path forward to enhance shareholder valueLocust Walk is a global life sciences transaction firm with exceptional...
Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon
16. September 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD...
Innovation Pharmaceuticals Plans for Clinical Trial of Oral Brilacidin for Ulcerative Colitis Program in 4th Quarter 2019
10. September 2019 09:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the...
Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities
29. Juli 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
Company building on momentum from recently executed licensing agreement with Alfasigma S.p.A.Focus on transitioning to oral formulations of first-in-class drug candidates, and securing additional...
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
22. Juli 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...